Nathan Weinstein

Stock Analyst at Aegis Capital

(0.16)
# 4,400
Out of 5,180 analysts
59
Total ratings
9.3%
Success rate
-33.07%
Average return

Stocks Rated by Nathan Weinstein

Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100$80
Current: $0.77
Upside: +10,289.61%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400$300
Current: $8.02
Upside: +3,640.65%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9$6
Current: $0.20
Upside: +2,870.30%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40$35
Current: $1.11
Upside: +3,053.15%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $1.84
Upside: +226.09%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35$30
Current: $3.42
Upside: +777.19%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $11.93
Upside: -16.18%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63$49
Current: $16.11
Upside: +204.16%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000$1,800
Current: $1.94
Upside: +92,683.51%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $6.21
Upside: +34,682.61%
Initiates: Buy
Price Target: $120
Current: $1.57
Upside: +7,543.31%
Maintains: Buy
Price Target: $9$10
Current: $0.45
Upside: +2,139.14%
Maintains: Buy
Price Target: $60$56
Current: $31.39
Upside: +78.40%
Maintains: Buy
Price Target: $26$27
Current: $3.54
Upside: +662.71%
Maintains: Buy
Price Target: $40$35
Current: $0.92
Upside: +3,717.21%
Initiates: Buy
Price Target: $12
Current: $1.11
Upside: +981.08%
Initiates: Buy
Price Target: $75
Current: $24.02
Upside: +212.24%
Maintains: Buy
Price Target: $104$88
Current: $2.12
Upside: +4,050.94%
Initiates: Buy
Price Target: $180
Current: $0.57
Upside: +31,396.06%
Maintains: Buy
Price Target: $195$135
Current: $10.65
Upside: +1,167.61%
Initiates: Buy
Price Target: $14
Current: $6.39
Upside: +119.09%
Maintains: Buy
Price Target: $180$220
Current: $14.46
Upside: +1,421.44%
Initiates: Buy
Price Target: $8.5
Current: $2.58
Upside: +229.46%